Healthcare
ViewRay, Inc.(VRAYQ)
Live Price
Offline$0.0001
+0.00% today
1Y Change
+900.00%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- โ
- Revenue Growth
- +45.8%
- EPS Growth
- +11.9%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ViewRay, Inc. (VRAYQ) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 900.0% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +45.8%, EPS growth of +11.9%, a dividend yield of 0.0%. What stands out right now is revenue +45.8%, EPS +11.9%, free cash flow -50.2% with operating margin -104.8% and ROIC -60.3%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VRAYQ price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+45.8% vs +7.6% peer median
Operating Margin
Below sector median
-104.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 29, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +45.8% and EPS at +11.9%, with operating margin around -104.8%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 5, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 29, 2026 | โ | +0.0% | +0.0% | โ |
2026 May 14, 2026 | โ | +0.0% | +0.0% | +0.0% |
2026 Mar 3, 2026 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VRAYQ
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
VRAYQ Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VRAYQ and SPY.
Company Overview
ViewRay, Inc.
Other OTC
ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally. It provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers through a network of direct sales force and distributors. ViewRay, Inc. was founded in 2004 and is headquartered in Denver, Colorado. On July 16, 2023, ViewRay, Inc., alongwith its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. On October 26, 2023, the voluntary petition of ViewRay , Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on July 16, 2023.
- Leadership
- Paul Ziegler Jr.
- IPO Date
- Aug 10, 2015
- Employees
- 295
- Street Address
- 1099 18th Street
- Mailing
- Denver, CO, 80202
- Region
- Denver, CO, US
- Reporting Currency
- USD
- Investor Line
- 440 703 3210
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 0.5
- Price/Sales
- 0.0
- Price/Book
- 0.1
Growth
- Revenue
- +45.8%
- EPS
- +11.9%
- Free Cash Flow
- -50.2%
Profitability
- Gross Margin
- 9.8%
- Operating Margin
- -104.8%
- Net Margin
- -105.2%
- ROE
- -85.3%
- ROIC
- -60.3%
Balance Sheet
- Debt/Equity
- 1.05
- Current Ratio
- 2.36
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.